Thomas Niel

Thomas Niel

InvestorPlace Contributor

Expertise: Micro-Cap Stocks, Shareholder Activist Stocks, Value Stocks

Education: Bachelors in Accounting, CFA Program Participant (Completed Level I in 2017)

About Thomas:
Thomas Niel is an investment writer at InvestorPlace. With a professional background in accounting and financial analysis, his understanding of both words and figures pays dividends when writing clear, concise stock analysis.

A value investor at heart, Thomas looks at the fundamentals. Peer analysis and earnings multiples rarely tell the whole story. But, Thomas believes valuation metrics are a great starting point to separate the wheat from the chaff.

His work has appeared at several websites, including Seeking Alpha and TipRanks. Outside of investment research, Thomas provides inbound marketing content to the investment management industry.

You can follow Thomas on Twitter and check out his track record on TipRanks.

Recent Articles

Novavax Stock Could Give Back More of Its Pandemic-Era Gains

By Thomas Niel, InvestorPlace Contributor

While trading at a very low multiple to the low end of earnings estimates, NVAX stock may still be trading at a premium.

An Upset Victory for FuboTV Stock Is Too Far Off to Make it a Buy Today

By Thomas Niel, InvestorPlace Contributor

You may think that this sports betting/streaming play is oversold, but a comeback for FUBO stock may take too long. There's no rush to bottom-fish in FUBO stock. If bullish on its future, take your time.

Steer Clear of VeChain After Its Spike on No News

By Thomas Niel, InvestorPlace Contributor

Investors should pass on VeChain, as when it comes to speculative cryptocurrencies, it's best to stick with general-use picks.

7 Micro-Cap Stocks to Make a Bet on in Q2

By Thomas Niel, InvestorPlace Contributor

They may be risky and under the radar, but these seven micro-cap stocks offer ample upside potential at today's prices.

The Crowd Has Wisely Soured on Cassava Sciences Stock

By Thomas Niel, InvestorPlace Contributor

As perceptions rise that its flagship drug candidate won't make it to market, steer clear of SAVA stock.

Load More